Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1

Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1

As breast cancer cells transition from letrozole-sensitive to letrozole-resistant, they over-express epidermal growth factor receptor (EGFR), mitogen-activated protein kinase (MAPK), and human epidermal growth factor receptor 2 (HER2) while acquiring enhanced motility and epithelial-to-mesenchymal t...

Full description

Bibliographic Details
Main Authors: Jankiben R. Patel, Bipika Banjara, Afia Ohemeng, A. Michael Davidson, Stephen M. Boué, Matthew E. Burow, Syreeta L. Tilghman
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Nutrients
Subjects:
breast cancer
endocrine resistance
letrozole
aromatase inhibitors
phytochemicals
cancer stem cells
Online Access:https://www.mdpi.com/2072-6643/15/7/1632

Internet

https://www.mdpi.com/2072-6643/15/7/1632

Similar Items